Start here if you're new
what it is
Ocular Therapeutix makes eye treatments, sells two approved products, and is trying to turn a drug-delivery platform into a much bigger retina business.
how it gets paid
Last year Ocular Therapeutix made $52M in revenue.
why growth slowed
Revenue fell 18.5% last year. $39M matters because it shows how lumpy this business can be.
what just happened
Revenue hit $39M, but EPS was still a deep -$1.15.
At a glance
B+ balance sheet — decent shape, but not bulletproof
60/100 earnings predictability — reasonably predictable
-$1.42 fy2025 eps est
$2B fy2026 rev est
n/a operating margin
xvary composite: 51/100 — below average
What they do
Ocular Therapeutix makes eye treatments, sells two approved products, and is trying to turn a drug-delivery platform into a much bigger retina business.
The edge is the delivery tech. Bioresorbable hydrogel platform → a drug gel that dissolves in the eye over time → so what: you can keep medicine in place without asking patients to come back for constant treatment. That matters because the company already has two marketed eye products and a Regeneron collaboration, while long-term debt is only $74 million, or 4% of capital.
How they make money
$52M
annual revenue · revenue declined -18.5% last year
total revenue
$52M
18.5%
The products that matter
post-surgical eye pain and inflammation therapy
DEXTENZA
$52M · 100% of current revenue
it's the entire commercial business today, and it declined 18.5% from last year. if this keeps shrinking, the company gets even more dependent on the pipeline.
all current sales
wet AMD drug candidate
AXPAXLI (OTX-TKI)
phase 3 data · feb 2026
positive Phase 3 data is why a company with $52M of declining revenue can still carry a roughly $2B market cap. in plain English: this asset is the thesis.
valuation driver
Key numbers
$2B
fy2026 revenue est
Street revenue expectations jump from $52M trailing sales to $2B next year. Plain English: the stock is priced for a commercial leap, not a steady climb.
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. Operating margin → money kept after running the business → so what: Ocular is still spending far more than it brings in.
$74M
long-term debt
Debt is only 4% of capital. Plain English: the balance sheet is cleaner than the income statement.
18.5%
annual revenue
Annual revenue fell to $52M. So while the story is about future growth, the current business is still shrinking.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $74M (4% of capital)
B+ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for OCUL right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue hit $39M, but EPS was still a deep -$1.15.
Revenue surged 166% vs. prior year in the latest quarter, while full-year revenue still came in at $52M, down 18.5%. Quiet part out loud: one strong quarter does not erase a n/a operating margin.
$39M
revenue
$1.15
eps
+166%
revenue vs. last year
the number that mattered
$39M matters because it shows how lumpy this business can be, but the bigger truth is that profits are still nowhere in sight.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is FDA timing or commercial disappointment for AXPAXLI in wet AMD.
med
AXPAXLI is carrying the valuation
A roughly $2B market cap sits on top of a business producing $52M in revenue today. Positive Phase 3 data helped. Approval timing, label details, and launch execution still matter.
If the H2 2026 NDA path slips or enthusiasm fades, the premium multiple gets hard to defend fast.
med
100% of current revenue comes from one declining product
DEXTENZA generated all $52M of revenue and declined 18.5% from last year. That means the existing business is not funding investor optimism with growth.
Any further commercial erosion leaves the company even more exposed to pipeline timing.
med
The operating model is still deeply underwater
A n/a operating margin means this is not a self-sustaining profit engine. You're underwriting future scale, not current economics.
When losses are this large, any delay forces the market to think harder about cash burn and financing risk.
med
Volatility is part of the product
Price stability is 5 / 100, beta is 1.2, and the stock has traded between $6 and $16 over the last 52 weeks. This name reprices on headlines, not on calm quarterly compounding.
Even if the long-term thesis works, your path there can be violent.
A failed or delayed AXPAXLI path would hit a stock already valued at 36.7x sales, while 100% of current revenue still depends on a shrinking $52M DEXTENZA franchise.
source: institutional data · regulatory filings · risk analysis
Pay attention to
regulatory calendar
AXPAXLI NDA timing in H2 2026
Management plans to accelerate the wet AMD filing. If that slips, investors will start asking why a 36.7x sales stock deserves a premium multiple today.
commercial metric
DEXTENZA revenue after an 18.5% decline
You do not need heroic growth here. You do need stabilization. Another weak quarter would make the current business look more like dead weight than proof of execution.
next report
Q1 2026 earnings on may 11, 2026
This is the first report after positive Phase 3 data. Watch whether management spends more time on launch prep, DEXTENZA repair, or capital needs.
launch prep
commercial build under the new cco
The January 2026 chief commercial officer hire matters because clinical wins do not launch themselves. If the team build looks thin, the market will notice.
Analyst rankings
earnings predictability
60 / 100
In human-speak: analysts do not see this as a smooth quarter-to-quarter story. Clinical names with one shrinking commercial product tend to surprise people.
average analyst target
$21.38
Fourteen analysts see roughly 95% upside from $10.98. Translation: the street believes AXPAXLI can do a lot of heavy lifting that current revenue does not.
source: institutional data
Institutional activity
institutional ownership data for OCUL is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$11
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive